Continuing professional development
From Mr K. Cooke
I commend Navjot Nannar for his comprehensive review of managing ankylosing spondylitis (AS). Having suffered from AS for nearly 40 years and with a wife who was a pharmacist until her retirement, I might be considered an expert patient.
The diagnosis of AS used to be notoriously slow but the symptoms are now more readily recognised. Confusingly, different AS patients can show different selections of symptoms and the severity of each can vary widely.
I have been taking the newly approved (for AS) antitumour necrosis factor agent adalimumab by self-injection and have just passed the 12-week review date. It has substantially improved my condition and brought great benefits to my lifestyle.
Dr Nannar descibes the association of AS with a genetic marker, HLA B27. Readers might like to know that other genetic factors have also been identified and that research continues into their relevance.Ken Cooke Ilkley, West Yorkshire
Citation: The Pharmaceutical Journal URI: 10032801
Recommended from Pharmaceutical Press
An innovative book which presents statistics in the context of clinical trials conducted during pharmaceutical drug development.£38.00Buy now